MicroRNA Array Analysis Finds Elevated Serum miR-1290 Accurately Distinguishes Patients with Low-Stage Pancreatic Cancer from Healthy and Disease Controls
- 30 June 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (13), 3600-3610
- https://doi.org/10.1158/1078-0432.ccr-12-3092
Abstract
Purpose: Our goal was to identify circulating micro RNA (miRNA) levels that could distinguish patients with low-stage pancreatic cancer from healthy and disease controls. Experimental Design: We measured 735 miRNAs in pancreatic cancer case and control sera by QRTPCR using TaqMan MicroRNA Arrays. After array analysis, we selected 18 miRNA candidates for validation in an independent set of cases and control samples. Results: Of the significantly elevated circulating miRNAs in patients with pancreatic cancer compared with controls, miR-1290 had the best diagnostic performance: receiver operating characteristic (ROC) analysis on miR-1290 serum level yielded curve areas (AUC) of 0.96 [95% confidence interval (CI), 0.91–1.00], 0.81 (0.71–0.91), and 0.80 (0.67–0.93), for subjects with pancreatic cancer (n = 41) relative to healthy controls (n = 19), subjects with chronic pancreatitis (n = 35), and pancreatic neuroendocrine tumors (n = 18), respectively. Serum miR-1290 levels were also significantly higher than healthy controls among patients with intraductal papillary mucinous neoplasm (IPMN; n = 20; AUC = 0.76, 0.61–0.91). Serum miR-1290 levels distinguished patients with low-stage pancreatic cancer from controls better than CA19-9 levels, and like CA19-9, higher miR-1290 levels predicted poorer outcome among patients undergoing pancreaticoduodenectomy. Greater numbers of miR-1290 transcripts were detected by FISH in primary pancreatic cancer and IPMN than normal pancreatic duct cells. miR-1290 influenced in vitro pancreatic cancer cell proliferation and invasive ability. Several other circulating miRNAs distinguished sera of patients with pancreatic cancer from those of healthy controls with AUCs >0.7, including miR-24, miR-134, miR-146a, miR-378, miR-484, miR-628-3p, and miR-1825. Conclusions: The detection of elevated circulating miR-1290 has the potential to improve the early detection of pancreatic cancer. Clin Cancer Res; 19(13); 3600–10. ©2013 AACR.Other Versions
This publication has 50 references indexed in Scilit:
- International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancerGut, 2012
- Breast cancer risk–associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expressionNature Genetics, 2012
- Frequent Detection of Pancreatic Lesions in Asymptomatic High-Risk IndividualsGastroenterology, 2012
- Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial NeoplasiaGastroenterology, 2012
- Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancerBritish Journal of Cancer, 2011
- Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst DevelopmentScience Translational Medicine, 2011
- Feasibility and Yield of Screening in Relatives From Familial Pancreatic Cancer FamiliesThe American Journal of Gastroenterology, 2011
- Imaging individual microRNAs in single mammalian cells in situNucleic Acids Research, 2009
- High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNANucleic Acids Research, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008